

Scott D Ramsey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/465585/publications.pdf>

Version: 2024-02-01

100
papers

6,024
citations

117625

34
h-index

76900

74
g-index

102
all docs

102
docs citations

102
times ranked

8726
citing authors

#	ARTICLE	IF	CITATIONS
1	Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 980-986.	1.6	642
2	Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report. <i>Value in Health</i> , 2005, 8, 521-533.	0.3	567
3	Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer Diagnosis. <i>Health Affairs</i> , 2013, 32, 1143-1152.	5.2	553
4	Cost-Effectiveness Analysis Alongside Clinical Trials – An ISPOR Good Research Practices Task Force Report. <i>Value in Health</i> , 2015, 18, 161-172.	0.3	539
5	Quality of life in survivors of colorectal carcinoma. , 2000, 88, 1294-1303.		285
6	Risk Factors for Financial Hardship in Patients Receiving Adjuvant Chemotherapy for Colon Cancer: A Population-Based Exploratory Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1608-1614.	1.6	246
7	Cost Effectiveness of Lung-Volume-Reduction Surgery for Patients with Severe Emphysema. <i>New England Journal of Medicine</i> , 2003, 348, 2092-2102.	27.0	218
8	Quality of life in long term survivors of colorectal cancer. <i>American Journal of Gastroenterology</i> , 2002, 97, 1228-1234.	0.4	214
9	Comparison of Survival Outcomes Among Cancer Patients Treated In and Out of Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju002.	6.3	178
10	Using Generalized Linear Models to Assess Medical Care Costs. <i>Health Services and Outcomes Research Methodology</i> , 2000, 1, 185-202.	1.8	175
11	Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 3014-3022.	1.6	170
12	Pilot Feasibility Study of an Oncology Financial Navigation Program. <i>Journal of Oncology Practice</i> , 2018, 14, e122-e129.	2.5	149
13	Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials. <i>JAMA Network Open</i> , 2018, 1, e181235.	5.9	130
14	A Health Economics Approach to US Value Assessment Frameworks – Summary and Recommendations of the ISPOR Special Task Force Report [7]. <i>Value in Health</i> , 2018, 21, 161-165.	0.3	113
15	On the use of survival analysis techniques to estimate medical care costs. <i>Journal of Health Economics</i> , 1999, 18, 365-380.	2.7	89
16	Patient-Level Estimates of the Cost of Complications in Diabetes in a Managed-Care Population. <i>Pharmacoeconomics</i> , 1999, 16, 285-295.	3.3	83
17	Characterizing Potentially Preventable Cancer- and Chronic Disease-Related Emergency Department Use in the Year After Treatment Initiation: A Regional Study. <i>Journal of Oncology Practice</i> , 2018, 14, e176-e185.	2.5	74
18	Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 1339-1348.	1.6	62

#	ARTICLE	IF	CITATIONS
19	Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2710-2717.	1.6	61
20	The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone. <i>Oncologist</i> , 2016, 21, 320-326.	3.7	59
21	Review of Recent US Value Frameworks—A Health Economics Approach: An ISPOR Special Task Force Report [6]. <i>Value in Health</i> , 2018, 21, 155-160.	0.3	52
22	Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non—Small-Cell Lung Cancer. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-10.	2.1	50
23	Updated Evaluation of the Cost-effectiveness of Lung Volume Reduction Surgery. <i>Chest</i> , 2007, 131, 823-832.	0.8	49
24	Addressing the Financial Burden of Cancer Treatment. <i>JAMA Oncology</i> , 2015, 1, 273.	7.1	49
25	The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study. <i>Health Economics (United Kingdom)</i> , 2001, 10, 245-256.	1.7	46
26	Design Issues for Conducting Cost-Effectiveness Analyses Alongside Clinical Trials. <i>Annual Review of Public Health</i> , 2001, 22, 129-141.	17.4	46
27	Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. <i>American Journal of Gastroenterology</i> , 2002, 97, 440-445.	0.4	46
28	Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. <i>BJU International</i> , 2011, 108, 851-856.	2.5	46
29	An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. <i>Genetics in Medicine</i> , 2003, 5, 353-363.	2.4	40
30	Impact of Prostate Cancer on Sexual Relationships: A Longitudinal Perspective on Intimate Partners' Experiences. <i>Journal of Sexual Medicine</i> , 2013, 10, 3135-3143.	0.6	38
31	Preliminary treatment considerations among men with newly diagnosed prostate cancer. <i>American Journal of Managed Care</i> , 2010, 16, e121-30.	1.1	38
32	Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer. <i>Gastroenterology</i> , 2003, 125, 1645-1650.	1.3	36
33	Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. <i>World Journal of Urology</i> , 2011, 29, 3-9.	2.2	36
34	Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. <i>American Journal of Managed Care</i> , 2010, 16, 678-86.	1.1	36
35	Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics. <i>Medical Decision Making</i> , 2013, 33, 463-471.	2.4	35
36	Cost Effectiveness of Gene Expression Profile Testing in Community Practice. <i>Journal of Clinical Oncology</i> , 2018, 36, 554-562.	1.6	35

#	ARTICLE	IF	CITATIONS
37	A Review of Quality-of-Life Evaluations in Prostate Cancer. <i>Pharmacoeconomics</i> , 1999, 16, 127-140.	3.3	34
38	Evaluation of Erlotinib in Advanced Non-Small Cell Lung Cancer: Impact on the Budget of a U.S. Health Insurance Plan. <i>Journal of Managed Care Pharmacy</i> , 2006, 12, 472-478.	2.2	32
39	Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 860-867.	2.5	30
40	An Economic Evaluation of Atorvastatin for Primary Prevention of Cardiovascular Events in Type 2 Diabetes. <i>Pharmacoeconomics</i> , 2008, 26, 329-339.	3.3	29
41	Economic analysis of lung volume reduction surgery as part of the national emphysema treatment trial. <i>Annals of Thoracic Surgery</i> , 2001, 71, 995-1002.	1.3	28
42	A New Model for Reimbursing Genome-Based Cancer Care. <i>Oncologist</i> , 2014, 19, 1-4.	3.7	28
43	S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2022, 114, 372-380.	6.3	28
44	Access to Information Sources and Treatment Considerations Among Men With Local Stage Prostate Cancer. <i>Urology</i> , 2009, 74, 509-515.	1.0	27
45	Surveillance endoscopy does not improve survival for patients with local and regional stage colorectal cancer. <i>Cancer</i> , 2007, 109, 2222-2228.	4.1	24
46	Survival and Lifetime Costs Associated With First-Line Bevacizumab Use in Older Patients With Metastatic Colorectal Cancer. <i>Oncologist</i> , 2014, 19, 892-899.	3.7	19
47	Addressing Skyrocketing Cancer Drug Prices Comes With Tradeoffs. <i>JAMA Oncology</i> , 2016, 2, 425.	7.1	19
48	Risk of Adverse Financial Events in Patients With Cancer: Evidence From a Novel Linkage Between Cancer Registry and Credit Records. <i>Journal of Clinical Oncology</i> , 2022, 40, 884-891.	1.6	18
49	Attitudes towards Genetic Screening for Predisposition to Colon Cancer among Cancer Patients, Their Relatives and Members of the Community. <i>Public Health Genomics</i> , 2003, 6, 29-36.	1.0	17
50	Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population. <i>International Journal of General Medicine</i> , 2011, 4, 481.	1.8	17
51	How State And Federal Policies As Well As Advances In Genome Science Contribute To The High Cost Of Cancer Drugs. <i>Health Affairs</i> , 2015, 34, 571-575.	5.2	17
52	Recruiting adults with osteoarthritis into an aquatic exercise class: Strategies for a statewide intervention. <i>Arthritis and Rheumatism</i> , 1998, 11, 455-462.	6.7	16
53	Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1208-1215.	6.3	16
54	Observational Study Designs for Comparative Effectiveness Research: An Alternative Approach to Close Evidence Gaps in Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 106-114.	0.8	15

#	ARTICLE	IF	CITATIONS
55	Coronary artery bypass grafting in Native Americans. <i>Journal of General Internal Medicine</i> , 2001, 16, 554-559.	2.6	14
56	Cost-Effectiveness of Lung Volume Reduction Surgery. <i>Proceedings of the American Thoracic Society</i> , 2008, 5, 406-411.	3.5	14
57	Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models. <i>EBioMedicine</i> , 2015, 2, 2062-2069.	6.1	14
58	Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response. <i>Breast</i> , 2015, 24, 3-11.	2.2	14
59	Implementing Lung Cancer Screening Using Low-Dose Computed Tomography: Recommendations From an Expert Panel. <i>Journal of Oncology Practice</i> , 2015, 11, e44-e49.	2.5	14
60	Information Seeking and Satisfaction with Information Sources Among Spouses of Men with Newly Diagnosed Local-Stage Prostate Cancer. <i>Journal of Cancer Education</i> , 2018, 33, 325-331.	1.3	14
61	Out-of-Pocket Costs for Tyrosine Kinase Inhibitors and Patient Outcomes in EGFR- and ALK-Positive Advanced Non-Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e130-e139.	2.9	12
62	Satisfaction with cancer care among American Indian and Alaska Natives in Oregon and Washington State: a qualitative study of survivor and caregiver perspectives. <i>Supportive Care in Cancer</i> , 2016, 24, 2437-2444.	2.2	11
63	Comorbidity is associated with higher risk of financial burden in Medicare beneficiaries with cancer but not heart disease or diabetes. <i>Medicine (United States)</i> , 2019, 98, e14004.	1.0	11
64	Cancer-Directed Therapy and Hospice Care for Metastatic Cancer in American Indians and Alaska Natives. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1138-1143.	2.5	10
65	Drug Price Inflation and the Cost of Assisted Death for Terminally Ill Patients—Death With Indignity. <i>JAMA Oncology</i> , 2017, 3, 15.	7.1	9
66	Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990–2015: Progress and Opportunities. <i>Oncologist</i> , 2017, 22, 304-310.	3.7	8
67	Practice-Changing Strategies to Deliver Affordable, High-Quality Cancer Care: Summary of an Institute of Medicine Workshop. <i>Journal of Oncology Practice</i> , 2013, 9, 54s-59s.	2.5	7
68	Cancer Stage in American Indians and Alaska Natives Enrolled in Medicaid. <i>American Journal of Preventive Medicine</i> , 2016, 51, 368-372.	3.0	7
69	Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 733-740.	2.1	7
70	Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras. <i>JCO Oncology Practice</i> , 2021, 17, e1728-e1737.	2.9	7
71	Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR+ and ALK+ Positive Non-Small-Cell Lung Cancer Treated in the Real-World. <i>Clinical Lung Cancer</i> , 2021, 22, e723-e733.	2.6	7
72	Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing. <i>American Health and Drug Benefits</i> , 2019, 12, 256-262.	0.5	7

#	ARTICLE	IF	CITATIONS
73	Does Economics Matter When Treating Advanced Non-Small Cell Lung Cancer?. <i>Oncologist</i> , 2002, 7, 179-180.	3.7	6
74	Performance Goals for an Adjunct Diagnostic Test to Reduce Unnecessary Biopsies After Screening Mammography: Analysis of Costs, Benefits, and Consequences. <i>Journal of the American College of Radiology</i> , 2016, 13, R81-R88.	1.8	6
75	Physician Ordering of Screening Ultrasound: National Rates and Association With State-Level Breast Density Reporting Laws. <i>Journal of the American College of Radiology</i> , 2020, 17, 15-21.	1.8	6
76	Using electronic health record data to identify comparator populations for comparative effectiveness research. <i>Journal of Medical Economics</i> , 2020, 23, 1618-1622.	2.1	6
77	Comparison of Health Care Utilization at the End of Life Among Patients With Cancer in Alberta, Canada, Versus Washington State. <i>JCO Oncology Practice</i> , 2020, 16, e1543-e1552.	2.9	6
78	A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer. <i>Journal of Medical Economics</i> , 2021, 24, 79-86.	2.1	6
79	Quality of life in survivors of colorectal carcinoma. <i>Cancer</i> , 2000, 88, 1294-1303.	4.1	6
80	Proposal to reimburse occupational medicine disease and injury claims through third party health insurance. <i>American Journal of Industrial Medicine</i> , 1994, 26, 147-154.	2.1	5
81	Comparison of Treatment, Cost, and Survival in Patients With Metastatic Colorectal Cancer in Western Washington, United States, and British Columbia, Canada. <i>JCO Oncology Practice</i> , 2020, 16, e425-e432.	2.9	5
82	Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 455-463.	2.5	5
83	Advanced Imaging and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer. <i>International Journal of Breast Cancer</i> , 2016, 2016, 1-10.	1.2	4
84	Computed Tomography Screening for Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 77.	7.4	4
85	Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers. <i>Contemporary Clinical Trials</i> , 2020, 95, 106037.	1.8	4
86	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). <i>JCO Oncology Practice</i> , 2021, 17, e1821-e1829.	2.9	4
87	Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, 523-530.	2.6	4
88	Pharmaco-Economic Impact of HMG-CoA Reductase Inhibitors in Type 2 Diabetes. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2001, 8, 127-132.	2.8	3
89	Gut Check: Can Cost-Effectiveness Analysis Help Eliminate Gastric Cancer in Asia?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 873-874.	2.5	3
90	Insurance Coverage and Aid-in-Dying Medication Costs—Reply. <i>JAMA Oncology</i> , 2017, 3, 1138.	7.1	3

#	ARTICLE	IF	CITATIONS
91	Lessons From Reporting National Performance Measures in a Regional Setting: Washington State Community Cancer Care Report. <i>Journal of Oncology Practice</i> , 2018, 14, e801-e814.	2.5	3
92	The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. <i>Cancer Epidemiology</i> , 2018, 55, 117-122.	1.9	3
93	A comparison of general, genitourinary, bowel, and sexual quality of life among long term survivors of prostate, bladder, colorectal, and lung cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 305-311.	1.0	3
94	Effect of Clinical Trial Participation on Costs to Payers in Metastatic Non-Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1225-e1234.	2.9	3
95	Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review. <i>Value in Health</i> , 2022, 25, 276-287.	0.3	3
96	Cost effectiveness of lung volume reduction surgery. <i>Chest Surgery Clinics of North America</i> , 2003, 13, 727-738.	0.7	2
97	Economic Impact of Imaging Overutilization in Cancer Care. <i>Journal of the American College of Radiology</i> , 2020, 17, 137-140.	1.8	2
98	History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-12.	2.1	1
99	Budget impact analysis of the DiviTum Tka assay in postmenopausal women with hormone receptor positive metastatic breast cancer. <i>Journal of Medical Economics</i> , 2021, 24, 1309-1317.	2.1	0
100	Practical Implementation of Universal Hepatitis B Virus Screening for Patients With Cancer. <i>JCO Oncology Practice</i> , 0, , .	2.9	0